Company / PP&E (Net)
Ovid Therapeutics Inc. PP&E (Net) History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$252.0K
FY2025
5-year range
$252.0K / $1.1M
FY2022-FY2025
Trend
-41.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
PP&E (Net) has declined for 3 consecutive years, from $1M in FY2022 to $252,000 in FY2025.
Based on SEC 10-K filings.
$252,000 in FY2025 with a 3-year CAGR of -39.7%.
Declined from $768,753 to $252,000 over the past 2 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -39.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Ovid Therapeutics Inc.'s pp&e (net) has declined for 3 consecutive years.
- 3-year CAGR of -39.7%, indicating a declining trend.
- In FY2025, pp&e (net) decreased 41.8% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.61 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $252.0K | -41.8% |
| FY2024 | $433.0K | -43.7% |
| FY2023 | $768.8K | -33.0% |
| FY2022 | $1.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026